The Musella Foundation gave a $50,000 grant back in 2010 to get this project going. Used by itself, it has pretty good results in a phase 1 trial:3 patents (out of 43) had long term partial responses of 54,34 and 28 months after a single injection of the treatment. They think combining it with a checkpoint inhibitor will make it work better, and it did in mice. It cures GBMs in mice, but now they have to prove the combination helps in people. There is a clinical trial of this combination for recurrent malignant glioma going on at Duke. See https://clinicaltrials.gov/ct2/show/NCT04547777 for details. The concept makes a lot of sense. Hope it pans out.